Document is current

Article History

Accepted: 4 September 2022

First Online: 21 October 2022

Change Date: 31 December 2022

Change Type: Update

Change Details: The complete section of ESM has been included in the original version of the article.

Declarations

:

: Open Access funding enabled and organized by CAUL and its Member Institutions.

: The data utilized in this study were sourced from clinical trials that were conducted according to the ethical principles of the Declaration of Helsinki. This research was considered appropriate to be conducted under the UTS Human Research Ethics Committee (UTS HREC REF NO. ETH18-2507).

: Amy Gye is an employee of Novartis Pharmaceuticals Australia. This research is part of an Industry Doctorate Program at the Centre for Health Economics Research and Evaluation, University of Technology Sydney in collaboration with Novartis Pharmaceuticals Australia. Novartis Pharmaceuticals Australia provides a Research Support Fee. Ms. Gye receives a salary from Novartis.

: Amy Gye is an employee of Novartis Pharmaceuticals Australia. No other disclosures were reported.

: Concept and design: Gye, Goodall, De Abreu Lourenco; acquisition of data: Gye; analysis and interpretation of data: Gye; drafting of the manuscript: Gye, Goodall, De Abreu Lourenco; critical revision of the paper for important intellectual content: Goodall, De Abreu Lourenco; supervision: Goodall, De Abreu Lourenco.

: Analysis of clinical trial data was conducted retrospectively, and ethics approval was granted by the University of Technology Sydney Human Research Ethics Committee.